Xpovio, Nexpovio(selinexor)
Nexpovio, Xpovio (selinexor) is a small molecule pharmaceutical. Selinexor was first approved as Xpovio on 2019-07-03. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target exportin-1.
Download report
Favorite
FDA Novel Drug Approvals 2019
Commercial
Trade Name
FDA
EMA
Xpovio
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Selinexor
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XPOVIO | Karyopharm Therapeutics | N-212306 RX | 2019-07-03 | 4 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| xpovio | New Drug Application | 2020-12-18 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
SELINEXOR, XPOVIO, KARYOPHARM THERAPS | |||
| 2027-12-18 | ODE*, ODE-346 | ||
| 2027-06-22 | ODE*, ODE-310 | ||
| 2026-07-03 | ODE*, ODE-257 | ||
| 2024-07-03 | NCE | ||
| 2023-06-22 | I-837 | ||
HCPCS
No data
Clinical
Clinical Trials
131 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | C92.0 | 13 | 6 | — | — | — | 17 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 5 | 3 | — | — | — | 6 | |
| Sarcoma | D012509 | 5 | 2 | — | — | — | 6 | ||
| Glioblastoma | D005909 | EFO_0000515 | 5 | 4 | — | — | — | 6 | |
| Myelodysplastic syndromes | D009190 | D46 | 2 | 2 | — | — | — | 4 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 1 | — | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | 3 | 2 | — | — | — | 3 | ||
| Melanoma | D008545 | 2 | 1 | — | — | — | 3 | ||
| Colorectal neoplasms | D015179 | 2 | 2 | — | — | — | 3 | ||
| Primary myelofibrosis | D055728 | D47.4 | 1 | 3 | — | — | — | 3 |
Show 31 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neurofibrosarcoma | D018319 | 2 | — | — | — | — | 2 | ||
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 2 | — | — | — | — | 2 | |
| Renal cell carcinoma | D002292 | 1 | — | — | — | — | 1 | ||
| Lung neoplasms | D008175 | C34.90 | 1 | — | — | — | — | 1 | |
| Fallopian tube neoplasms | D005185 | 1 | — | — | — | — | 1 | ||
| Rectal neoplasms | D012004 | 1 | — | — | — | — | 1 | ||
| B-cell lymphoma | D016393 | 1 | — | — | — | — | 1 | ||
| Ewing sarcoma | D012512 | EFO_0000173 | 1 | — | — | — | — | 1 | |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
| Esophageal neoplasms | D004938 | C15 | 1 | — | — | — | — | 1 |
Show 14 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SELINEXOR |
| INN | selinexor |
| Description | Selinexor sold under the brand name Xpovio among others, is a selective inhibitor of nuclear export used as an anti-cancer medication. It works by blocking the action of exportin 1 and thus blocking the transport of several proteins involved in cancer-cell growth from the cell nucleus to the cytoplasm, which ultimately arrests the cell cycle and leads to apoptosis. It is the first drug with this mechanism of action.
|
| Classification | Small molecule |
| Drug class | exportin 1 inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1 |
Identifiers
| PDB | — |
| CAS-ID | 1393477-72-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545185 |
| ChEBI ID | — |
| PubChem CID | 71481097 |
| DrugBank | DB11942 |
| UNII ID | 31TZ62FO8F (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
XPO1
XPO1
Organism
Homo sapiens
Gene name
XPO1
Gene synonyms
CRM1
NCBI Gene ID
Protein name
exportin-1
Protein synonyms
chromosome region maintenance 1 homolog, Chromosome region maintenance 1 protein homolog, exportin 1 (CRM1 homolog, yeast), exportin-1 (required for chromosome region maintenance)
Uniprot ID
Mouse ortholog
Xpo1 (103573)
exportin-1 (Q6P5F9)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,515 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
34,220 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more